Comparison of the ocular hypotensive effects of bimatoprost and timolol-dorzolamide combination in patients with elevated intraocular pressure: A 6-month study

Acta Ophthalmologica Scandinavica

Volumn 85, Issue 1, 2007, Pages 80-83

  Ozturk, Faruk ^a   Ermis, Sitki Samet ^a,b   Inan, Umit Ubeyt ^a  

^a AFYON KOCATEPE UNIVERSITY   (Turkey)

^b NONE   (Turkey)

Author keywords

Bimatoprost; Dorzolamide; Ocular hypertension; Primary open angle glaucoma; Timolol

Indexed keywords

BIMATOPROST; DORZOLAMIDE PLUS TIMOLOL;

ADULT; AGED; ARTICLE; BITTER TASTE; BURNING SENSATION; CLINICAL TRIAL; CONJUNCTIVAL HYPEREMIA; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG EFFICACY; DRUG MECHANISM; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; DRY EYE; DYSPNEA; EYELID DISEASE; FEMALE; FOLLOW UP; HUMAN; INTRAOCULAR HYPERTENSION; INTRAOCULAR PRESSURE; LONG TERM CARE; MAJOR CLINICAL STUDY; MALE; MONOTHERAPY; OPEN ANGLE GLAUCOMA; OPEN STUDY; PERIMETRY; PRIORITY JOURNAL; PROSPECTIVE STUDY; RANDOMIZED CONTROLLED TRIAL; SIDE EFFECT; STATISTICAL SIGNIFICANCE; STUDENT T TEST; TREATMENT DURATION; VISUAL SYSTEM EXAMINATION;

AGED; AMIDES; ANTIHYPERTENSIVE AGENTS; CLOPROSTENOL; DRUG THERAPY, COMBINATION; FEMALE; GLAUCOMA, OPEN-ANGLE; HUMANS; INTRAOCULAR PRESSURE; LIPIDS; MALE; MIDDLE AGED; OCULAR HYPERTENSION; PROSPECTIVE STUDIES; SINGLE-BLIND METHOD; SULFONAMIDES; THIOPHENES; TIMOLOL;

EID: 33846408301     PISSN: 13953907     EISSN: 16000420     Source Type: Journal    
DOI: 10.1111/j.1600-0420.2006.00754.x     Document Type: Article

References (18)

1. Advanced Glaucoma Intervention Study Investigators (2000): The Advanced Glaucoma Intervention Study (AGIS): 7. The relationship between control of intraocular pressure and visual field deterioration. Am J Ophthalmol 130: 429-440.
2. Boyle JE, Ghosh K, Gieser DK & Adamsons IA (1998): A randomized trial comparing the dorzolamide-timolol combination given twice daily to monotherapy with timolol and dorzolamide. Ophthalmology 105: 1945-1951.
3. Brubaker RF, Schoff EO, Nau CB, Carpenter SP, Chen K & Vandenburgh AM (2001): Effects of AGN 192024, a new ocular hypotensive agent, on aqueous dynamics. Am J Ophthalmol 131: 19-24.
4. Coleman AL, Lerner F, Bernstein P & Whitcup SM (2003): A 3-month randomized controlled trial of bimatoprost (Lumigan) versus combined timolol and dorzolamide (Cosopt) in patients with glaucoma or ocular hypertension. Ophthalmology 110: 2362-2368.
5. Day DG, Sharpe ED, Beischel CJ, Jenkins JN, Stewart JA & Stewart WC (2005): Safety and efficacy of bimatoprost 0.03% versus timolol maleate 0.5% dorzolamide 2% fixed combination. Eur J Ophthalmol 15: 336-342.
6. Early Manifest Glaucoma Trial Investigators (2002): Reduction of intraocular pressure and glaucoma progression: Results from the Early Manifest Glaucoma Trial. Arch Ophthalmol 120: 1268-1279.
7. Eisenberg DL, Toris CB & Camras CB (2002): Bimatoprost and travoprost: A review of recent studies of two new glaucoma drugs. Surv Ophthalmol 47 (Suppl 1): 105-115.
8. Fechtner RD, Airaksinen PJ, Getson AJ, Lines CR & Adamsons IA (2004): Efficacy and tolerability of the dorzolamide 2%/timolol 0.5% combination (Cosopt) versus 0.005% (Xalatan) in the treatment of ocular hypertension or glaucoma: Results from two randomized clinical trials. Acta Ophthalmol Scand 82: 42-48.
9. Hutzelmann J, Owens S, Shedden A, Adamsons I & Vargas E (1998): Comparison of the safety and efficacy of the fixed combination of dorzolamide/timolol and the concomitant administration of dorzolamide and timolol: A clinical equivalence study. International Clinical Equivalence Study Group. Br J Ophthalmol 82: 1249-1253.
10. Krauss AHP & Woodward DF (2004): Update on the mechanism of action of bimatoprost: A review and discussion of new evidence. Surv Ophthalmol 49: S5-S11.
11. Lippa EA, Schuman JS, Higginbotham EJ et.al. (1991): MK-507 versus sezolamide. Comparative efficacy of two topically active carbonic anhydrase inhibitors. Ophthalmology 98: 308-312.
12. Neufeld AH, Bartels SP & Liu JH (1983): Laboratory and clinical studies on the mechanism of action of timolol. Surv Ophthalmol 28: 286-292.
13. Stewart WC, Sharpe ED, Harbin TS, Pastor SA, Day DG, Holmes KT & Stewart JA (2000): Brimonidine 0.2% versus dorzolamide 2% each given three times daily to reduce Intraocular pressure. Am J Ophthalmol 129: 723-727.
14. Strahlman ER, Vogel R, Tipping R & Clineschmidt CM (1996): The use of dorzolamide and pilocarpine as adjunctive therapy to timolol in patients with elevated intraocular pressure. Ophthalmology 103: 1283-1293.
15. Strohmaier K, Snyder E, DuBiner H & Adamsons I (1998): The efficacy and safety of the dorzolamide-timolol combination versus the concomitant administration of its components. Ophthalmology 105: 1936-1944.
16. Sugrue MF, Harris A & Adamsons I (1997): Dorzolamide hydrocholoride: a topically active carbonic anhydrase inhibitor for the treatment of glaucoma. Drugs Today 35: 283-298.
17. Toris CB, Camras CB & Yablonski ME (1993): Effects of PhXA41, a new prostaglandin F2 alpha analogue, on aqueous humour dynamics in human eyes. Ophthalmology 100: 1297-1304.
18. Whitcup SM, Cantor LB, Vandenburgh AM & Chen K (2003): A randomized, double-masked, multicentre clinical trial comparing bimatoprost and timolol for the treatment of glaucoma and ocular hypertension. Br J Ophthalmol 87: 57-62.